Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Smoldering Plasma Cell Myeloma Clear all
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Hiltonol, Citarinostat, Lenalidomide, PVX-410
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
Interventions
(Anti-KIR)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced May 21, 2026, 11:11 PM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Bone Marrow Biopsy, Dexamethasone, Lenalidomide, Pomalidomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Amyloidosis
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
207
States / cities
Little Rock, Arkansas • Berkeley, California • Burlingame, California + 141 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Anakinra (IL-1Ra), Dexamethasone acetate
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions
defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis
Dietary Supplement · Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced May 21, 2026, 11:11 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
PVX-410
Biological
Lead sponsor
OncoPep, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Niles, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Anakinra, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Placebo
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Selinexor
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Early Phase 1 Interventional Results available
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide
Radiation · Drug · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Biopsy Specimen Radiography, Lenalidomide, Vaccine Therapy
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Not applicable Interventional Results available
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Plant based meals
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 11:11 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced May 21, 2026, 11:11 PM EDT
Withdrawn Early Phase 1 Interventional
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions
DKK1
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced May 21, 2026, 11:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders
Interventions
Blood draw for the laboratory assessment
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
1,665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 11:11 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Asymptomatic Myeloma
Interventions
Atezolizumab (1200mg via IV infusion)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced May 21, 2026, 11:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions
Teclistamab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Irene Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced May 21, 2026, 11:11 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Siltuximab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Chicago, Illinois • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced May 21, 2026, 11:11 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
Interventions
Prolonged Fasting Intervention, EDUCATION CONTROL
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced May 21, 2026, 11:11 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 11:11 PM EDT